Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03241745 · ClinicalTrials.gov registry record · Phase 2
A Study of Nivolumab in Selected Uterine Cancer Patients
A Phase 2 study of Uterine Cancer and Endometrial Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 8
- Study locations
NCT03241745: Completed Phase 2 study of Uterine Cancer and Endometrial Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03241745 is a Phase 2 study of Uterine Cancer and Endometrial Carcinoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 35 participants, below the 270-participant average among 27 other Uterine Cancer trials with a reported enrollment target (87% lower). The trial reports 8 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03241745, a Phase 2 study of Uterine Cancer and Endometrial Carcinoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer. The investigators also want to find out what effects, good or bad, nivolumab has on the patient and their cancer.
Primary Outcome
will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)
Conditions Studied
Interventions
- DRUG Nivolumab
Study Locations (8)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Pennsylvania
- Lehigh Valley Health Network - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-08-03 |
| Est. Completion | 2024-04-01 |
| Phase | Phase 2 |
What the finished NCT03241745 record still lists
NCT03241745 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 270-participant average among 27 other Uterine Cancer trials with a reported enrollment target (87% lower).
The record links to 7 conditions, with Uterine Cancer appearing as the primary indexed condition, and to 1 intervention - of which Nivolumab is the first listed.
NCT03241745 lists 8 locations in 3 states (New York, New Jersey, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT03241745 about?
NCT03241745 is a clinical study titled "A Study of Nivolumab in Selected Uterine Cancer Patients". The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer. The investigators also want to find out what effects, good or bad, nivolumab has on the patient and their cancer.
What is the current status of trial NCT03241745?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2017-08-03. Estimated completion is 2024-04-01.
What conditions does trial NCT03241745 study?
This clinical trial studies the following conditions: Uterine Cancer, Endometrial Carcinoma, Leiomyosarcoma, Clear Cell Carcinoma, Undifferentiated Sarcoma.
What interventions are being tested in trial NCT03241745?
The interventions under investigation include: Nivolumab (DRUG).
Who is sponsoring clinical trial NCT03241745?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03241745 being conducted?
This trial has 8 study locations across New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03241745's enrollment target sits among peer trials
35 16th of 27 higher than 12 of 27 other Uterine Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uterine Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
RECRUITING · Phase 2
-
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
RECRUITING · Phase 2
-
[18F]FES PET/.CT in Uterine Cancer
RECRUITING · Phase 2
-
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
RECRUITING · Phase 2
-
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Image-Guided Gynecologic Brachytherapy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI